"Will Doctors Disappear at This Rate?"... AI Endoscope Diagnoses Early Gastric Cancer More Accurately Than Specialists

Weisen Unveils Diagnostic Accuracy for Lesion Invasion Depth at VNAGE 2025

Weisen, a company specializing in medical artificial intelligence (AI), announced on the 3rd that it participated in the Vietnam Gastroenterology Association (VNAGE 2025), held in Vietnam for two days starting October 31, and released the latest research findings on early gastric cancer diagnosis using its AI endoscope, "Weimed Endo."

Professor Kim Yuna of Yonsei University Gangnam Severance Hospital presented research results on early gastric cancer diagnosis using the AI endoscope "Weimed Endo" at "VNAGE 2025" held in Ninh Binh, Vietnam, on the 31st of last month. Weisen

This research was a clinical trial conducted by the team of Professors Kim Jihyun and Kim Yuna from the Division of Gastroenterology at Yonsei University Gangnam Severance Hospital. Professor Kim Yuna personally presented the results, sharing a comparative analysis of diagnostic accuracy between AI software and endoscopy specialists based on actual clinical data.

The results showed that the AI achieved a sensitivity of 96%, specificity of 95%, and overall accuracy of 96%, which is significantly higher than the accuracy of endoscopy specialists (71%). Notably, the AI maintained consistent diagnostic accuracy regardless of the size or shape of the lesions, demonstrating its potential for objective and stable diagnosis.

This study is significant in that it demonstrates the AI's ability not only to detect early gastric cancer but also to predict the depth of lesion invasion at a clinical level comparable to or exceeding that of specialists. It suggests that, in the future, AI could become a key tool to enhance physicians' decision-making during real-time diagnosis and treatment planning in endoscopic procedures.

According to the company, Professor Kim Yuna's presentation at VNAGE 2025 drew keen interest, with active questions and discussions from local medical professionals. Kim Kyungnam, CEO of Weisen, stated, "These research results are very encouraging, as Weimed Endo has taken the precision and consistency of early gastric cancer diagnosis to the next level," adding, "We will further accelerate our business performance and global market expansion based on clinical trust."

This content was produced with the assistance of AI translation services.